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Abstract
Background: Pericardial constriction is a serious complication of tuberculous pericardial effusion that occurs in up to a
quarter of patients despite anti-tuberculosis chemotherapy. The impact of human immunodeficiency virus (HIV) infection on
the incidence of constrictive pericarditis following tuberculous pericardial effusion is unknown.
Methods and Results: We conducted a prospective observational study to determine the association between HIV infection
and the incidence of constrictive pericarditis among 185 patients (median age 33 years) with suspected tuberculous
pericardial effusion. These patients were recruited consecutively between March and October 2004 on commencement of
anti-tuberculosis treatment, from 15 hospitals in Cameroon, Nigeria and South Africa. Surviving patients (N=119) were
assessed for clinical evidence of constrictive pericarditis at 3 and 6 months of follow-up. Clinical features of HIV infection
were present in 42 (35.2%) of the 119 patients at enrolment into the study. 66 of the 119 (56.9%) patients consented to HIV
testing at enrolment. During the 6 months of follow-up, a clinical diagnosis of constrictive pericarditis was made in 13 of the
119 patients (10.9 %, 95% confidence interval [CI] 5.9–18%). Patients with clinical features of HIV infection appear less likely
to develop constriction than those without (4.8% versus 14.3%; P=0.08). None of the 33 HIV seropositive patients
developed constriction, but 8 (24.2%, 95%CI 11.1–42.3%) of the 33 HIV seronegative patients did (P=0.005). In a
multivariate logistic regression model adjusting simultaneously for several baseline characteristics, only clinical signs of HIV
infection were significantly associated with a lower risk of constriction (odd ratio 0.14, 95% CI 0.02–0.87, P=0.035).
Conclusions: These data suggest that HIV infection is associated with a lower incidence of pericardial constriction in
patients with presumed tuberculous pericarditis.
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Introduction
Constrictive pericarditis is a serious complication of tuberculous
pericarditis that is associated with high morbidity and mortality of
3–15% following pericardiectomy [1]. Prior to the introduction of
effective anti-tuberculosis chemotherapy, up to 50% of patients
with effusive tuberculous pericarditis progressed to the constrictive
stage of the disease [2]. The introduction of rifampicin-based anti-
tuberculosis treatment in the 1970’s resulted in the reduction of
the incidence of constriction to about 25% in patients with effusive
tuberculous pericarditis [3,4]
In the last two decades, the human immunodeficiency virus
(HIV) pandemic has had a significant effect on the epidemiology of
pulmonary and extra-pulmonary tuberculosis, but the impact of
HIV infection on the development of pericardial fibrosis in
tuberculous pericarditis is not known [5]. This question is relevant
because IL-13-secreting CD4
+ TH2 cells, which are reduced by
HIV, regulate fibrogenesis directly, through stimulating collagen
synthesis by fibroblasts and indirectly by promoting TGF-b1
production by macrophages [6]. Furthermore, fewer granulomata
have been observed in HIV infected tuberculous pericarditis
patients with severely depleted CD4 lymphocytes, suggesting that
there may be less propensity to develop pericardial fibrosis in HIV-
infected individuals with tuberculous pericardial effusion [7].
We hypothesised that people with HIV-associated tuberculous
pericardial effusion may have a lower incidence of pericardial
constriction than those with pericardial tuberculosis and no evidence
of HIV infection during 6 months of anti-tuberculosis chemother-
apy. We tested this hypothesis by assessing the incidence of clinical
signs of constrictive pericarditis in survivors of tuberculous
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Management of Pericarditis in Africa (IMPI Africa) registry [8].
Methods
The IMPI Africa registry was a multi-centre, prospective,
observational study of patients with presumed tuberculous
pericarditis who were admitted consecutively to 15 referral
hospitals in Cameroon, Nigeria, and South Africa. The project
was approved by the local research ethics committees (listed at the
end of the paper) and all participants gave written informed
consent. The study was designed to assess the clinical presentation,
initial management, and outcome of patients with suspected
tuberculous pericarditis in the HIV era. The design of the study
and baseline characteristics of the participants enrolled in the
registry are described in detail elsewhere [8]. Briefly, the
participants were recruited between March 1, 2004 and October
31, 2004. The diagnosis of tuberculous pericarditis was deter-
mined by clinical assessment, and diagnostic evaluation generally
included ultrasound, electrocardiogram, and chest X-ray. In
keeping with the observational nature of the study and the
prespecified aim of documenting physician practice across the sub-
continent, no attempt was made to standardize the diagnostic
approach or diagnostic procedures and microbiological confirma-
tion was conducted at the discretion of the attending physician.
On enrolment into the study, clinical features of human
immunodeficiency virus (HIV) infection were determined by
standard criteria [9] and HIV serological testing was offered,
where possible, following voluntary counselling. The CD4 T cell
count was not recorded in this registry.
Patients with effusive pericardial disease on enrolment were
assessed clinically at three and six months of follow-up for clinical
evidence of constrictive pericarditis, which was defined as
persistent signs of elevated systemic venous pressure in the absence
of a pericardial effusion [10] The finding of a clinical diagnosis of
constrictive pericarditis at either the 3 month or 6 month follow up
visit constituted the outcome of interest. Only those patients with
no clinical evidence of constriction at 3 months were reassessed for
evidence of constriction at 6 months.
Data were analysed using Epi Info 3.3.2 (CDC, Atlanta, GA).
We used the Chi-squared test or Fisher’s exact test (as appropriate)
to assess probabilities of significant differences between propor-
tions and logistic regression to test which factors among presence
of clinical signs of HIV infection, age, sex, or cardiac tamponade
were associated with constrictive pericarditis at 6 months of follow-
up. Serological HIV status could not fit into the logistic regression
model since none of the HIV seronegative patients developed
constriction. All significance tests were two-tailed and statistical
significance was defined at the alpha level of 0.05.
Figure 1. Study flow chart of patients with presumed tuberculous pericarditis.
doi:10.1371/journal.pone.0002253.g001
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185 patients with presumed tuberculous pericarditis (median
age 33, range 14–87 years) were studied (Fig. 1). On enrolment,
there were three patients out of 185 (1.6%) who were diagnosed
with constrictive pericarditis, none of whom had clinical features
of HIV infection; one of the three consented to HIV testing and
tested negative. These three patients were excluded from the
current analysis. An additional sixty-three patients were excluded
from the analysis for the following reasons: (i) death before clinical
assessment at three or six months (N=31); (ii) follow-up was either
telephonic or the clinical assessment was not possible for other
reasons (N=32) (Fig. 1). There were no significant differences in
the baseline clinical characteristics between the patients who were
excluded and those who were included in the prospective analysis
of incidence and determinants of pericardial constriction (Table 1).
Overall, a clinical diagnosis of constrictive pericarditis was made
in 13/119 participants who were followed up and assessed
clinically at three and six months (10.9%; 95% confidence interval
[CI] 5.9–18%) (Fig. 1). Patients with clinical features of HIV
infection were less likely than those without to develop constriction
(4.8% [2/42] versus 14.3% [11/77]; P=0.08) (Fig. 1, Fig. 2). Sixty
six of the 119 patients consented to HIV testing on enrolment into
the study, 33 (50%) of whom were HIV sero-positive. None of the
HIV positive patients developed constriction compared to 8
(24.2%) HIV negative patients (P=0.005) (Fig. 1, Fig. 2).
We evaluated whether the following baseline characteristics
were associated with the risk of constrictive pericarditis: age, sex,
HIV infection, pericardiocentesis, adjunctive steroid use, and
haemodynamic instability at enrolment (Table 2). In the univariate
analysis, clinical evidence of HIV infection was the factor which
approached statistical significance (P=0.08). We constructed a
multivariate logistic regression model to adjust simultaneously for
all the above factors, and found only clinical evidence of HIV
infection was associated with a reduced risk of constriction (odd
ratio 0.14, 95% CI 0.02–0.87, P=0.035) (Table 2).
Discussion
In patients with pericardial effusion presumed to be due to
tuberculosis, the presence of clinical features of HIV infection and
positive HIV serology appear to be associated with a lower
Table 1. Comparison of baseline characteristics of patients
included and excluded from analysis.
Characteristic
Excluded
(n=66)
Included
(n=119) P-value
Age median (range), years 33 (14–69) 33 (15–87) 0.178
Gender
Female 29 (43.9) 53 (44.5)
Male 37 (56.1) 66 (55.5) 0.937
Clinical features of HIV infection
Yes 32 (48.5) 42 (35.2)
No 34 (51.5) 77 (64.7) 0.079
Serological HIV
Yes 20 (66.7) 33 (50.0)
No 10 (33.3) 33 (50.0) 0.128
NYHA
++ Functional Class
I 10 (15.2) 29 (24.3)
II 25 (37.9) 44 (37.0)
III 16 (24.2) 31 (26.1)
IV 15 (22.7) 15 (12.6) 0.216
Pericardiocentesis
Yes 1 (14.3) 25 (28.4)
No 6 (85.7) 63 (71.6) 0.420
Adjunctive steroid use
Yes 37 (56.1) 72 (60.5)
No 29 (43.9) 47 (39.5) 0.556
Haemodynamic instability**
Yes 23 (34.9) 31 (26.1)
No 43 (65.1) 88 (74.0) 0.207
Values are median (range) and absolute counts (percentages);
++NYHA, New York Heart Association (I, No limitation of physical activity; II,
Slight limitation of physical activity; III, Marked limitation of physical activity;
and IV, Unable to carry out any physical activity without discomfort);
**Pulse rate more than 100 bpm, Systolic blood pressure less than 100 mmHg
and or tamponade requiring centesis.
doi:10.1371/journal.pone.0002253.t001
Figure 2. A summary of the incidence of clinical constriction categorised by clinical features of HIV infection and by HIV sero-
status.
doi:10.1371/journal.pone.0002253.g002
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months of anti-tuberculosis treatment. This study is, to the best of
our knowledge, the first demonstration of this apparent protective
effect of HIV infection and immmunosupression against the
development of pericardial fibrosis. The observation is, however,
consistent with the finding that HIV-associated pulmonary
tuberculosis is associated less with lung fibrosis and cavitation,
and more with a disseminated pattern of disease in patients with
advanced immunosuppression [11].
Constrictive pericarditis occurs within six months in up to 25% of
patients with tuberculous pericardial effusion despite treatment with
anti-tuberculosis medication and corticosteroids [3,4]. Therefore,
the overall frequency of pericardial constriction of 10.9% in this
registry is in the lower range of the rates that have been recorded in
other prospective series. However, the frequency of constriction of
24.2% in patients known to be HIV sero-negative in our study is
similar to the historic rate recorded in the pre-HIV era [3,4].
Pericardial constriction is known to occur up to two years following
an episode of effusive pericardial tuberculosis. Therefore, the short
follow-up of six months may have under-estimated the incidence of
constriction in our cohort, and these findings apply to constriction
that develops within three to six months of follow-up.
Our study has several limitations. First, the six month mortality
rate for those with clinical evidence of HIV infection was 40%,
compared with 17% in those who were clinically HIV uninfected
(17%), and the exact cause of death was not determined [12]. Bias
will have been introduced if death intervened in the former group
before patients could present with clinically detectable constrictive
pericarditis. Alternatively some may have died from intractable
heart failure from early constriction.
Second, the simple clinical observational design of the registry
meant that the diagnosis of constriction was based on non-invasive
clinical and echocardiographic criteria, and the tuberculous
aetiology of the pericardial disease was confirmed only 7% of
the cohort [8]. This practice, however, reflects routine clinical care
in resource-poor settings of many African countries. The registry
was an observational study that was designed to capture the
contemporary practice and factors affecting outcome in patients
who are treated for tuberculous pericarditis [8,13].
Finally, not all patients were tested for HIV. HIV status could be
confirmed in slightly more than half of the cases with no cases of
constriction being observed among the few HIV seropositive
patients. This precluded the inclusion of proven HIV status in the
multivariate model. There was, however, internal consistency of the
association of clinical signs of HIV infection and confirmed HIV
infection, on the one hand, and the incidence of constriction on the
other hand. The sensitivity and specificity of clinical HIV for
confirmed HIV was 76% and 88%, respectively, in this study[8].
It is worthy to note that the trend towards a lower frequency of
pericardial constriction in HIV positive patients was observed in
an earlier Zimbabwean study where only 4 patients out of 58 (i.e.,
7%) were shown to have signs of constriction over a longer
observation period of 18 months [14]. In comparison a study done
in South Africa in the 1980s presumably in HIV sero-negative
individuals showed constriction in 11% of patients over a 2 year
period [15]. Whilst the Zimbabwean study on HIV sero-positive
patients did not however have sufficient power to substantiate this
claim, we show that there may be external validity to the
observation, provided that it is confirmed in appropriate studies.
We have found, in the first prospective observational study of
the impact of HIV infection on the incidence of constrictive
pericarditis following tuberculous pericardial effusion, that HIV
infection is associated with a reduced incidence of the develop-
ment of constrictive pericarditis. These observations suggest that
the immune suppression associated with HIV reduces the risk of
the development of pericardial fibrosis.
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